Source: EQS Group AG
DGAP-News: STADA Arzneimittel AG: STADA strengthens its branded product portfolio by purchasing the Flexitol(R) rights for UK and Ireland - a dermatological range in the area of hand and foot care
DGAP-News: STADA Arzneimittel AG / Key word(s): Miscellaneous
STADA Arzneimittel AG: STADA strengthens its branded product portfolio
by purchasing the Flexitol(R) rights for UK and Ireland - a
dermatological range in the area of hand and foot care
30.06.2014 / 10:27
---------------------------------------------------------------------
Bad Vilbel, June 30, 2014 - The British affiliate of STADA Arzneimittel AG,
Thornton & Ross Ltd., purchased the production and distribution rights for
the Flexitol(R) brand product portfolio in the United Kingdom and Ireland.
The net purchase price for the rights to the Flexitol(R) product range is
10 million pounds sterling (approximately Euro 12.49 million at current
exchange rates) payable in cash subject to adjustments for inventory. The
sellers are the LaCorium group of companies based in Sydney, Australia. The
purchase does not include any production facilities. In order to optimize
cost of sales, it is planned to transfer the production of nearly all of
the products sold in UK and Ireland to Thornton & Ross' in house
manufacturing facilities.
The product package comprises 15 prescription-free (OTC) and prescribable
(OTX) products in the area of hand and foot care. In 2013, net sales
generated in the United Kingdom and Ireland with this dermatological range
was approximately 3.3 million pounds sterling (approximately Euro 4.1
million at current exchange rates). In 2013 the Flexitol(R) product
portfolio posted an EBITDA margin which is significantly above the average
in the STADA Group.
"The acquisition of the Flexitol(R) dermatological range fits perfectly
with our strategy of further accelerating the expansion of
attractive-margin branded products. We will benefit from the purchase in
terms of product sales in the United Kingdom and Ireland", says Hartmut
Retzlaff, Chairman of the Executive Board of STADA Arzneimittel AG.
"Another interesting point of the acquisition is that the strongest selling
product in the United Kingdom is positioned in the prescribable area and is
included in the reimbursement list of the National Health Service in the
United Kingdom", adds Retzlaff.
Additional information for analysts:
STADA Arzneimittel AG / Investor Relations / StadastraÃe 2-18 / 61118 Bad
Vilbel - Germany / Phone: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-506
/ e-mail: communications@stada.de
Additional information for journalists:
STADA Arzneimittel AG / Media Relations / StadastraÃe 2-18 / 61118 Bad
Vilbel - Germany / Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-506
/ e-mail: press@stada.de
Or visit us in the Internet at http://www.stada.com.
End of Corporate News
---------------------------------------------------------------------
30.06.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: STADA Arzneimittel AG
StadastraÃe 2-18
61118 Bad Vilbel
Germany
Phone: +49 (0)6101 603- 113
Fax: +49 (0)6101 603- 506
E-mail: communications@stada.de
Internet: www.stada.de
ISIN: DE0007251803, DE0007251845,
WKN: 725180, 725184,
Indices: MDAX
Listed: Regulierter Markt in Düsseldorf, Frankfurt (Prime
Standard); Freiverkehr in Berlin, Hamburg, Hannover,
München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
275779 30.06.2014